Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis

Sacral neuromodulation - when and for who

(2021) Marcelo Mass-Lindenbaum et al.   International Braz J Urol

Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis

(2021) Hadi Mostafaei et al.   European Urology Focus

Intravaginal eletrical stimulation for bladder training method

(2021) Cássio L. Z. Riccetto   International Braz J Urol

Current pharmacotherapy of overactive bladder

(2021) Evgenyi I. Kreydin et al.   International Braz J Urol

International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR

(2020) David Staskin et al.   JOURNAL OF UROLOGY

Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis

(2020) Greta Lozano-Ortega et al.   DRUGS & AGING

Evaluating vibegron for the treatment of overactive bladder

(2020) Tomasz Rechberger et al.   EXPERT OPINION ON PHARMACOTHERAPY

A double‐blind, randomized, placebo‐controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan

(2020) Yao‐Chi Chuang et al.   LUTS-Lower Urinary Tract Symptoms

Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks

(2019) Sanbao Chai et al.   BMJ Open Diabetes Research & Care

Vibegron, a Novel Potent and Selective β 3 -Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study

(2018) Masaki Yoshida et al.   EUROPEAN UROLOGY

Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis

(2018) Con Kelleher et al.   EUROPEAN UROLOGY

The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis

(2018) Shanshan Wu et al.   Expert Opinion On Drug Safety

Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study

(2018) Dong Gil Shin et al.   NEUROUROLOGY AND URODYNAMICS

The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial

(2017) Sender Herschorn et al.   JOURNAL OF UROLOGY

Comparison of solifenacin and fesoterodine in treatment of overactive bladder

(2015) Önder Ercan et al.   SAUDI MEDICAL JOURNAL

Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder

(2014) Osamu Yamaguchi et al.   BJU INTERNATIONAL

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER

(2014) S. A. Kaplan et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia

(2014) Hann-Chorng Kuo et al.   NEUROUROLOGY AND URODYNAMICS

Efficacy and Safety of the Selective β3-Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study

(2014) Osamu YAMAGUCHI et al.   LUTS-Lower Urinary Tract Symptoms

Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder

(2013) David Ginsberg et al.   BJU INTERNATIONAL

A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder

(2013) C. Park et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

A randomised, double-blind, parallel design, multi-institutional, non-inferiority phase IV trial of imidafenacin versus fesoterodine for overactive bladder

(2013) K.-S. Lee et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: Results of a real-life clinical study

(2013) Hironobu Akino et al.   INTERNATIONAL JOURNAL OF UROLOGY

Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial

(2013) Osamu Yamaguchi et al.   INTERNATIONAL JOURNAL OF UROLOGY

A phase II dose-ranging study of mirabegron in patients with overactive bladder

(2013) Christopher R. Chapple et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

Flexible-Dose Fesoterodine in Elderly Adults with Overactive Bladder: Results of the Randomized, Double-Blind, Placebo-Controlled Study of Fesoterodine in an Aging Population Trial

(2013) Adrian Wagg et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Effect of Fesoterodine in Vulnerable Elderly Subjects with Urgency Incontinence: A Double-Blind, Placebo Controlled Trial

(2013) Catherine E. DuBeau et al.   JOURNAL OF UROLOGY

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

(2013) Sender Herschorn et al.   UROLOGY

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

(2012) Vik Khullar et al.   EUROPEAN UROLOGY

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Efficacy and Safety of Flexible Dose Fesoterodine in Men and Women with Overactive Bladder Symptoms Including Nocturnal Urinary Urgency

(2012) Jeffrey P. Weiss et al.   JOURNAL OF UROLOGY

Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial

(2011) Momokazu Gotoh et al.   INTERNATIONAL JOURNAL OF UROLOGY

The Association of Adiposity and Overactive Bladder Appears to Differ by Gender: Results From the Boston Area Community Health Survey

(2011) Carol L. Link et al.   JOURNAL OF UROLOGY

National Community Prevalence of Overactive Bladder in the United States Stratified by Sex and Age

(2011) Karin S. Coyne et al.   UROLOGY

Efficacy, Safety and Tolerability of Fesoterodine in Asian Patients with Overactive Bladder

(2011) Osamu YAMAGUCHI et al.   LUTS-Lower Urinary Tract Symptoms

Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial

(2010) Steven A. Kaplan et al.   BJU INTERNATIONAL

β−Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder

(2010) Brian J. Limberg et al.   CELL AND TISSUE RESEARCH

Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder

(2010) Franklin Chu et al.   CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial

(2009) Sender Herschorn et al.   BJU INTERNATIONAL

Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial

(2009) M. D. Vardy et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder

(2009) Yukio Homma et al.   INTERNATIONAL JOURNAL OF UROLOGY

Randomized, Double-blind, Placebo-controlled Trial of Flexible-dose Fesoterodine in Subjects With Overactive Bladder

(2009) Roger R. Dmochowski et al.   UROLOGY

Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms

(2008) Sender Herschorn et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study

(2008) M.-S Choo et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder

(2008) Yukio Homma et al.   INTERNATIONAL JOURNAL OF UROLOGY

Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women

(2008) Rebecca Rogers et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

Trospium 60 mg Once Daily (QD) for Overactive Bladder Syndrome: Results from a Placebo-Controlled Interventional Study

(2008) Roger R. Dmochowski et al.   UROLOGY

Treatment With Solifenacin Increases Warning Time and Improves Symptoms of Overactive Bladder: Results From VENUS, a Randomized, Double-Blind, Placebo-Controlled Trial

(2008) Mickey M. Karram et al.   UROLOGY